Custom-Made cancer vaccine shows promise in early trial

NCT ID NCT02600949

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing a personalized peptide vaccine for people with advanced pancreatic or colorectal cancer that has spread. The vaccine is made from each patient's own tumor cells and blood, aiming to train the immune system to attack the cancer. The study will check if the vaccine is safe and feasible to make and give, and will also look at how well it controls the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
personalized peptide vaccine (made from patient's own tumor cells and blood)
What this could lead to
If it works, this could point toward a personalized treatment that helps the immune system attack advanced pancreatic or colorectal cancer.
What could go wrong
This is a very early phase 1 trial, so the main goal is safety and feasibility, not effectiveness. The vaccine may not work for everyone, and there are risks of side effects like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.